Now 76 patient organisations from 60 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 76 organisations from 60 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest members

  • Azerbaijan: Charter Of "Fighting Leukemia" Public Union
  • Peru: ESPERANTRA
  • Germany: Parents' Organisation for Children with CML (Elternverein für Kinder mit CML e.V.)
  • Hong Kong: Adult Blood Cancer Group
  • Sudan: Charity Organization for patients with CML

See the list of CML groups in the Network, and our worldwide map.

ASH Interviews on CML by PatientPower now available

patientpower-andrew-schorrThe following video interviews done by our partner Andrew Schorr of PatientPower have just been published and are available as webstreams:

  • A CML Advocate's Perspective on News from ASH 2012: Interview with Greg Stephens, National CML Society
  • The latest in CML: a Global Patient Advocate's Perspective with Jan Geissler, CML Advocates Network
  • An Expert’s Perspective on Changing CML Treatment Options: Dr. Moshe Talpaz discusses whether or not the "big guns"of treatment should be used up front or saved as a later option
  • Ponatinib Study Brings Positive Results For the Most Resistant Types of CML, Dr. Jorge Cortes

 See the video interviews here

CML Horizons 2013: Registration has now started

cmlhz13-logo-250pxWe are looking forward to our 2nd CML Horizons conference held at the Hilton Prague Old Town, Prague, on 3-5 May 2013. The CML Steering Committee has worked hard to ensure that the conference includes topics of importance to the CML patient community and provides a unique opportunity for participants to share experiences and best practice. The conference will again feature a good mix of medical sessions with world-renowned CML experts like Tim Hughes from Australia, Gianantonio Rosti from Italy, Dina Ben Yehuda from Israel, Katerina Machova from the Czech Republic and Fabio Efficace from Italy, as well as sessions with advocacy topics e.g. on substandard drugs and generics, e-advocacy and social media, advocating to policy makers or how to run patient meetings.

Leaders of leukemia patient advocacy organisations are eligible to participate in this conference. More information can be found at http://www.cmladvocates.net/cmlhorizons2013

 

Read more ...

News on CML from the 2012 ASH Conference – our Patients' Perspective

At the 54th annual conference of the American Society for Hematology (ASH 2012), 159 results from clinical studies on CML were presented: 36 were presented orally, and 123 were featured on posters. We have personally chosen a selection of these in order to summarize the most important news e.g. updated data and new drugs in CML therapy, a new milestone to achieve <10% BCR-ABL at 3 months, "deep molecular remission" as a pre-requisite for a possible cessation of therapy, and Interferon combination studies.

(English, German and Hebrew versions by Giora & Jan, Russian translation by Sodeystvie, Chinese translation by Shanghai Roots & Shoots, Serbian translation by CML Serbia, Arabic translation donated by Nicola Srouji - thank you!)

  

Translations:

English

German

Russian

Hebrew

Chinese

French

Arabic

Serbian

Read more ...

Results of our pilot survey on adherence just published in "Journal of Patient Compliance" (Vol 2 Issue 4)

The "Journal of Patient Compliance" (Vol 2 Issue 4) has just published our scientific article on the patient-driven pilot survey on adherence in CML:

Optimal jpccoveradherence to oral cancer therapy is of key importance to maximise treatment effectiveness in patients. With the advance of molecular target therapies, cancer treatment in more and more indications is transforming from in-hospital care towards oral treatment in an outpatient setting. With cancer becoming a chronic disease, patients are often required to take the drug indefinitely on a daily basis. Ensuring an optimal adherence to treatment over the long-term period could be a challenge. As data on the driving factors of nonadherence in oncology is scarce, a pan-European workgroup of the CML Advocates Network has conducted a pilot study which has unveiled differences of non-adherence between countries, administration types and use of adherence tools in Chronic Myeloid Leukemia. This pilot study has provided the groundwork for a larger global adherence study that is currently ongoing in 12 languages.

Read more ...

Now 68 patient organisations from 55 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 68 organisations from 55 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest members "CML SA" (South Africa)ZAGRLJAJ (Bosnia and Herzegovina) and "The Association for Blood Cancer Patients Aid" (Poland). See the list of CML groups in the Network, and our worldwide map.

Leukemia Patient Advocates Foundation launches CML Adherence Study in 12 countries on 22/09/2012 – and needs your help!

hilfe3The Leukemia Patient Advocates Foundation, the legal host of the CML Advocates Network, is proud to announce the launch of phase 2 of its International CML Adherence Survey. The survey will launch in 12 countries on International CML Awareness Day (22 Sept 2012). As it is organized by the non-profit patient community, this research work urgently needs your support now: If you are a CML patient treated with TKI, please participate. If you are a doctor treating CML patients: Please encourage your patients to participate!

Read more ...

Adherence: If you could see it through my eyes... (CancerWorld)

2013 patient voiceOncologists have been shocked by the growing body of evidence showing that many cancer patients are failing to take their drugs as prescribed, even when there is strong evidence to show they will benefit, and the side-effects are not considered serious. In a recent article of the magazine "CancerWorld", Giora Sharf, Estelle Lecointe and Stella Kyriakides try to explain why this may be happening. They urge oncologists to be more aware of their patients’ doubts and concerns about their medication, and to help them feel more comfortable about discussing their problems with adherence. Read the full article here.

Now also in Italian: Video "What you need to know about adherence to therapy"

adherence-video-italian-200pxTaking medication exactly as prescribed is not always easy for many patients with chronic myeloid leukaemia, also known as CML.  But, it's important. Adherence, or taking the medication as prescribed by the doctor, has a strong impact on the effectiveness of treatment.  "Chronic Myeloid Leukemia: What you need to know about adherence to therapy" is a new video that educates patients with CML about the importance of adherence to treatment. Now also available in Italian language (and English)!

Read more ...

EHA Patient Advocacy Session: Quality of Life - do patients perceive it the same way as doctors do?

panel-200Patients, physicians and researchers all have a unique perspective on quality of life. However, does a patient perceive it the same way as their physician? With Quality of Life becoming more and more important when hematological diseases are turning into chronic diseases, this year’s “Patient Advocacy Session” at the European Hematology Association’s Annual Congress 2012 provided key insights into the patients and professionals’ perspectives on this important issue. The session, defined by the EHA Patient Working Group and chaired by Jan Geissler of the CML Advocates Network and Androulla Eleftheriou of the Thalassaemia International Federation, has become an integral part of EHA’s congress.

Read more ...

Now 66 patient organisations from 53 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 66 organisations from 53 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest member "Thai CML Patients Group" from Thailand!

Now 65 patient organisations from 52 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 65 organisations from 52 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest member "CML Tunisia"!

Please donate!

Please donate!

LogIn

EU e-Privacy Directive